Please assess the completion status of the following clinical trial:

Trial Title: CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Bone marrow blasts \>= 5% that develops after remission, no restriction on prior number of relapses or regimens~* Eastern Cooperative Oncology Group (ECOG) 0-2~* At least a 3-month duration of remission prior to relapse~* Participants with relapse after allogeneic transplantation are included~* Up to 1 cycle of hypomethylating agent monotherapy at time of relapse is allowed, must be discontinued at least 14 days prior to start of salvage induction~* Serum total bilirubin =\< 2.0 mg/dL, unless considered due to Gilbert?s disease or leukemia involvement~* Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =\< 3 times the upper limit of normal, unless considered due to leukemia involvement~* Alkaline phosphatase =\< 3 times the upper limit of normal, unless considered due to leukemia involvement~* Serum creatinine =\< 2.0 mg/dL, or creatinine clearance \> 40 mL/min based on Cockcroft-Gault glomerular filtration rate (GFR)~* Ability to give full informed consent on their own~* Females of reproductive potential (postmenopausal for less than 24 consecutive months) must have a negative pregnancy~Exclusion Criteria:~* Currently receiving targeted therapy for FLT3 (cytokine receptor tyrosine kinase class III), IDH1, or IDH2 (isocitrate dehydrogenase, 1, 2) mutations and intent to continue use; prior use of targeted therapy for such mutations is allowed, but agents should be discontinued 1 week prior to enrollment~* Acute promyelocytic leukemia~* Second malignancy that would limit survival by less than 2 years~* New York Heart Association class III or VI~* Left ventricular ejection fraction \< 50%~* History of coronary stent placement that requires mandatory continuation of dual-antiplatelet therapy~* History of Wilson?s disease or other copper handling disorders~* Hypersensitivity to cytarabine, daunorubicin, or liposomal products~* Active invasive fungal infection~* Active bacterial or viral infection manifesting as fevers or hemodynamic instability within the past 72 hours~* Lifetime cumulative daunorubicin-equivalent anthracycline dose \> 368 mg/m\^2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (CPX-351, gemtuzumab ozogamicin) (Type: EXPERIMENTAL): INDUCTION: Patients receive liposome-encapsulated daunorubicin 44mg/m2 - cytarabine 100mg/m2 IV over 90 minutes on days 1, 3, and 5, and gemtuzumab ozogamicin 3 mg/m2 (max 4.5 mg) IV over 120 minutes on day 7, or days 4 and 7, or days 1, 4, and 7 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi receive consolidation therapy at the discretion of the treating physician and/or proceed to allogeneic HSCT.

Based on this trial design, predict the completion outcome and termination type (if applicable).